The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma

Sudha Kodali, Laura Kulik, Antonio D'Allessio, Eleonora De Martin, Abdul Rahman Hakeem, Monica Lewinska, Stacie Lindsey, Ken Liu, Zorana Maravic, Madhukar S. Patel, David Pinato, Ashwin Rammohan, Nicole Rich, Marco Sanduzzi Zamparelli, David W. Victor, Carmen Vinaxia, Elizabeth W. Brombosz, Augusto Villanueva, Tim Meyer, Nazia SelznerRafik Mark Ghobrial, Mohamed Rela, Gonzalo Sapisochin, Maen Abdelrahim, Vatche Agopian, Deniz Balci, Jordi Bruix, Tanios S. Bekaii-Saab, Marina Berenguer, Prashant Bhangui, Sherrie Bhoori, Albert Chi Yan Chan, Stephen L. Chan, Alfred Kow Wei Chieh, Francois Durand, Bijan Eghtesad, Ahmed Elsabbagh, Karim J. Halazun, Milind Javle, Taizo Hibi, Dong Hwan Jung, Korosh Khalili, Jeong Min Lee, Robert Lewandowski, Pal Dag Line, Josep Maria Llovet, Vincenzo Mazzaferro, Valeria Mas, Neil Mehta, Helen Morement, Grainne O'Kane, Valerie Paradis, Neehar Parikh, Anjana Pillai, Wojtek Polak, James Pomposelli, Lorenza Rimassa, Amit Singal, Arvinder Singh Soin, Parissa Tabrizian, Christian Toso, Juan Valle, Eric Vibert, Arndt Vogel, Jessica Zucman Rossi, Kymberly Watt, Andrea Wilson Woods

Research output: Contribution to journalArticlepeer-review

Abstract

Liver transplantation (LT) provides the best long-term survival outcomes for patients with liver cancer. As a result, the field of transplant oncology has grown greatly over the past few decades, and many centers have expanded their criteria to allow increased access to LT for liver malignancies. Center-level guidelines and practices in transplant oncology significantly vary across the world, leading to debate regarding the best course of treatment for this patient population. An international consensus conference was convened by the International Liver Transplantation Society and the International Liver Cancer Association on February 1-2, 2024, in Valencia, Spain to establish a more universal consensus regarding LT for oncologic indications. The conference followed the Delphi process, followed by an external expert review. Consensus statements were accepted regarding patient assessment and waitlisting criteria, pretransplant treatment (including immunotherapy) and downstaging, living donor LT, post-LT patient management, and patient-and caregiver-related outcomes. The multidisciplinary participants in the consensus conference provided up-to-date recommendations regarding the selection and management of patients with liver cancer being considered for LT. Although participants deferred to center protocols in many cases, there was great interest in safely expanding access to LT for patients with larger tumor burden and biologically amenable lesions.

Original languageEnglish (US)
Pages (from-to)815-831
Number of pages17
JournalLiver Transplantation
Volume31
Issue number6
Early online dateFeb 28 2025
DOIs
StatePublished - Jun 1 2025

Keywords

  • HCC
  • consensus development conference
  • intrahepatic cholangiocarcinoma
  • liver transplantation
  • transplant oncology
  • Waiting Lists/mortality
  • Liver Neoplasms/surgery
  • Humans
  • Liver Transplantation/standards
  • Treatment Outcome
  • Living Donors
  • Carcinoma, Hepatocellular/surgery
  • Bile Duct Neoplasms/surgery
  • Societies, Medical/standards
  • Consensus
  • Patient Selection
  • Spain
  • Delphi Technique
  • Cholangiocarcinoma/surgery
  • Practice Guidelines as Topic

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Divisions

  • Abdominal Transplant
  • Gastroenterology and Hepatology
  • Medical Oncology

Fingerprint

Dive into the research topics of 'The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this